[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: COVID-Vac Combined Vector Vaccine (manufactured by Hetero): Component I: Recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL||Component II: Recombinant adenovirus serotype 5 particles containing SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL||Component I and Component II will be given with a gap of 21 DaysControl Intervention1: Gam-COVID-Vac (Sputnik V \u00e2?? Manufactured for RDIF; Russia): Component I: Recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL|| Component II: Recombinant adenovirus serotype 5 particles containing SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL|| Component I and Component II will be given with a gap of 21 Days", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: COVID-Vac Combined Vector Vaccine (manufactured by Hetero): Component I: Recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL||Component II: Recombinant adenovirus serotype 5 particles containing SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL||Component I and Component II will be given with a gap of 21 Days", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Gam-COVID-Vac (Sputnik V \u00e2?? Manufactured for RDIF; Russia): Component I: Recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL|| Component II: Recombinant adenovirus serotype 5 particles containing SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL|| Component I and Component II will be given with a gap of 21 Days", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "2;Days0-21 (manufactured by Hetero)", "treatment_id": 344, "treatment_name": "Covid-vac combined vector vaccine", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "2;Days0-21 (Sputnik V \u2013 Manufactured for RDIF, Russia) ", "treatment_id": 532, "treatment_name": "Gam-covid-vac", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "N/A", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: COVID-Vac Combined Vector Vaccine (manufactured by Hetero): Component I: Recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL||Component II: Recombinant adenovirus serotype 5 particles containing SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL||Component I and Component II will be given with a gap of 21 DaysControl Intervention1: Gam-COVID-Vac (Sputnik V \u00e2?? Manufactured for RDIF; Russia): Component I: Recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL|| Component II: Recombinant adenovirus serotype 5 particles containing SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL|| Component I and Component II will be given with a gap of 21 Days", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: COVID-Vac Combined Vector Vaccine (manufactured by Hetero): Component I: Recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL||Component II: Recombinant adenovirus serotype 5 particles containing SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL||Component I and Component II will be given with a gap of 21 Days", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Gam-COVID-Vac (Sputnik V \u00e2?? Manufactured for RDIF; Russia): Component I: Recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL|| Component II: Recombinant adenovirus serotype 5 particles containing SARS-CoV-2 protein S gene; in the amount of (1.0\u00c2\u00b10.5) \u00d1? 10 power 11 particles per dose of 0.5 mL|| Component I and Component II will be given with a gap of 21 Days", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]